| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
Erinacine A
Erinacin A manufacturers
- Erinacine A
-
- $848.00
-
2026-07-27
- CAS:156101-08-5
- Purity: 99.82%
- Supply Ability: 10g
|
| | Erinacine A
Erinacin A Basic information |
| Product Name: | Erinacine A
Erinacin A | | Synonyms: | Erinacine A
Erinacin A;Cyclohept[e]indene-8-carboxaldehyde, 2,3,3a,4,5,5a,6,7-octahydro-3a,5a-dimethyl-1-(1-methylethyl)-6-(β-D-xylopyranosyloxy)-, (3aR,5aR,6S)-;(+)-Erinacin A | | CAS: | 156101-08-5 | | MF: | C25H36O6 | | MW: | 432.55 | | EINECS: | | | Product Categories: | | | Mol File: | 156101-08-5.mol |  |
| | Erinacine A
Erinacin A Chemical Properties |
| Boiling point | 610.8±55.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | solubility | Acetonitrile: Soluble
Methanol: Soluble | | form | Solid | | pka | 13.01±0.70(Predicted) | | color | Light yellow to yellow |
| | Erinacine A
Erinacin A Usage And Synthesis |
| Uses | (+)-Erinacin A is a diterpenoid derivative isolated from the mushroom Hericium erinaceum. It can increase the catecholamine and nerve growth factor (NGF) content in the central nervous system of rats. | | in vivo | (+)-Erinacin A (1, 5 and 10 mg/kg, i.p.; single dose) inhibits neuronal cell death in SAM rats with transient stroke and suppresses the expression of inflammatory cytokines in SAM brain tissues with transient stroke[4].
(+)-Erinacin A (1, 2 and 5 mg/kg, i.p.; once a day for 5 days) significantly reduces tumor volume in DLD-1 xenograft mice[5]. | Animal Model: | DLD-1 xenograft mouse model[5]. | | Dosage: | 1, 2 and 5 mg/kg | | Administration: | Intraperitoneal injection (i.p.) once a day for 5 days | | Result: | Inhibited tumor volume by 60%, 32% and 26%.
|
| Animal Model: | SAM rats with transient stroke[4]. | | Dosage: | 1, 5 and 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.) single dose | | Result: | Induced NeuN immune response in the entire brain region of SAM rats, and increased the number of NeuN cells.
Inhibited the activation of iNOS and p38/MAPK pathways and the expression of CHOP and nitrotyrosine proteins in rat brain tissue.
|
| | References | [1] HIROKAZU KAWAGISHI ∗ . Erinacines A, B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum[J]. Tetrahedron Letters, 1994, 35 10: Pages 1569-1572. DOI: 10.1016/s0040-4039(00)76760-8
[2] CHIEN-CHANG LU . Inhibitory effect of Erinacines A on the growth of DLD-1 colorectal cancer cells is induced by generation of reactive oxygen species and activation of p70S6K and p21[J]. Journal of Functional Foods, 2016, 21: Pages 474-484. DOI: 10.1016/j.jff.2015.12.031
[3] KAM-FAI LEE. Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson’s Disease.[J]. Antioxidants, 2020. DOI: 10.3390/antiox9020137
[4] PEI-CHIEN HSU . Erinacine A attenuates glutamate transporter 1 downregulation and protects against ischemic brain injury[J]. Life sciences, 2022, 306: Article 120833. DOI: 10.1016/j.lfs.2022.120833 |
| | Erinacine A
Erinacin A Preparation Products And Raw materials |
|